Who
Gary S. Jacob
Chief Development Officer
Company insider
Files Form 4 as: Chief Development Officer, OKYO Pharma; CEO and President, Hepion Pharmaceuticals; Director, Virpax Pharmaceuticals; Director and Other, Cardiff Oncology; Executive Chairman, Synergy Pharmaceuticals; Chief Executive Officer, Callisto Pharmaceuticals.
In numbers
- Trades disclosed
- 97
- Buys
- 9
- Sells
- 0
- Bought
- $194K
- Sold
- $0
- Companies
- 6
- Companies where not an officer
- 2
- First trade
- 17 Mar 2006
- Last trade
- 21 Jul 2026
- Last filed
- 7 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Jul 2026filed 7 Aug 2026 | OKYO OKYO PharmaBiotechnology | SEC FORM 4 Bought | $4,9003,500 at $1.40 | filing |
| 21 Jul 2026filed 7 Aug 2026 | OKYO OKYO PharmaBiotechnology | SEC FORM 4 Bought | $4,9003,500 at $1.40 | filing |
| 21 Jul 2026filed 23 Jul 2026 | OKYO OKYO PharmaBiotechnology | SEC FORM 4 Code A | $4,9003,500 at $1.40 | filing |
| 21 Jul 2026filed 23 Jul 2026 | OKYO OKYO PharmaBiotechnology | SEC FORM 4 Code A | $4,9003,500 at $1.40 | filing |
| 19 Feb 2024filed 21 Feb 2024 | Hepion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —85,000 at $0.00 | filing |
| 19 May 2022filed 19 May 2022 | OKYO OKYO PharmaBiotechnology | SEC FORM 4 Bought | $50K12,500 at $4.00 | filing |
| 1 Jan 2022filed 5 Jan 2022 | Virpax Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —12,091 at $0.00 | filing |
| 10 Jun 2021filed 15 Jun 2021 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code J | —28,858 at $0.00 | filing |
| 10 Jun 2021filed 15 Jun 2021 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code J | —293 at $0.00 | filing |
| 10 Jun 2021filed 15 Jun 2021 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code J | —218 at $0.00 | filing |
| 10 Jun 2021filed 15 Jun 2021 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code J | —223 at $0.00 | filing |
| 10 Jun 2021filed 15 Jun 2021 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code J | —223 at $0.00 | filing |
| 10 Jun 2021filed 15 Jun 2021 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code J | —530 at $0.00 | filing |
| 10 Jun 2021filed 15 Jun 2021 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code J | —755 at $0.00 | filing |
| 10 Jun 2021filed 15 Jun 2021 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code J | —44,734 at $0.00 | filing |
| 18 May 2021filed 20 May 2021 | Hepion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 7 Apr 2021filed 9 Apr 2021 | Virpax Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —13,183 at $0.00 | filing |
| 23 Mar 2021filed 23 Mar 2021 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $20K1,900 at $10.42 | filing |
| 23 Mar 2021filed 23 Mar 2021 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $4,888470 at $10.40 | filing |
| 17 Feb 2021filed 19 Feb 2021 | Virpax Pharmaceuticals | SEC FORM 4 Bought | $24K3,500 at $6.79 | filing |
News
No headline names them, or the companies they trade most, lately.